← Back to Search

Behavioural Intervention

rTMS for Suicidal Ideation in Opioid Users

N/A
Recruiting
Research Sponsored by Baylor College of Medicine
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be male or female aged 18-60 years old
Female subjects must be non-nursing and not pregnant at the times of fMRI experiments and rTMS treatment;
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 7 days

Summary

This trial is investigating if a treatment targeting the OFC/dSTR connectivity will reduce compulsive reward-seeking behavior in patients with a history of opioid abuse and suicidal ideation.

Who is the study for?
This trial is for adults aged 18-60 with active suicidal thoughts, enrolled in The Menninger Clinic, experiencing depression, and have used opioids. They must understand the study and consent to participate. Women can't be pregnant or nursing. Participants cannot have metal implants that interfere with MRI or TMS procedures.
What is being tested?
The study tests if Repetitive Transcranial Magnetic Stimulation (rTMS), a non-invasive brain stimulation technique, affects brain connectivity related to compulsive behavior and mood control in opioid users with suicidal tendencies compared to sham (fake) treatment.
What are the potential side effects?
rTMS may cause discomfort at the stimulation site, headache, lightheadedness, or seizures in rare cases. It's generally considered safe but might not be suitable for those sensitive to magnetic fields.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am between 18 and 60 years old.
Select...
I am not pregnant or breastfeeding.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~7 days
This trial's timeline: 3 weeks for screening, Varies for treatment, and 7 days for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Functional Connectivity between the orbitofrontal cortex (OFC) and dorsal striatum in opioid users or opioid-related patients versus healthy subjects
rTMS changes in dorsal striatum responses between those receiving active stimulation versus sham stimulation

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: Active rTMSExperimental Treatment1 Intervention
5 sessions of active rTMS
Group II: Sham rTMSPlacebo Group1 Intervention
5 sessions of sham rTMS
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Repetitive Transcranial Magnetic Stimulation (rTMS)
2019
Completed Phase 2
~780

Find a Location

Who is running the clinical trial?

National Institute on Drug Abuse (NIDA)NIH
2,607 Previous Clinical Trials
3,329,855 Total Patients Enrolled
6 Trials studying Suicide
54,103 Patients Enrolled for Suicide
American Foundation for Suicide PreventionOTHER
34 Previous Clinical Trials
9,762 Total Patients Enrolled
22 Trials studying Suicide
8,365 Patients Enrolled for Suicide
Baylor College of MedicineLead Sponsor
1,028 Previous Clinical Trials
6,030,082 Total Patients Enrolled
3 Trials studying Suicide
275 Patients Enrolled for Suicide

Media Library

Repetitive Transcranial Magnetic Stimulation (rTMS) (Behavioural Intervention) Clinical Trial Eligibility Overview. Trial Name: NCT05489042 — N/A
Suicide Research Study Groups: Sham rTMS, Active rTMS
Suicide Clinical Trial 2023: Repetitive Transcranial Magnetic Stimulation (rTMS) Highlights & Side Effects. Trial Name: NCT05489042 — N/A
Repetitive Transcranial Magnetic Stimulation (rTMS) (Behavioural Intervention) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05489042 — N/A
~0 spots leftby Jan 2025